Page 1

Particulars Sun Pharmaceutical Industries Limited Registered Office : Sun Pharma Advanced Research Centre , Tandalja , Vadodara - 390012 . Corporate Office : Sun House , CTS No. 201 B / 1 , Western Express Highway , Goregaon ( E ) , Mumbai - 400063 Tel .: +91 22 4324 4324 . CIN : L24230GJ1993PLC019050 , Website : www.sunpharma.com Statement of Audited Consolidated Financial Results for the Quarter and Year ended March 31 , 2021 ( In Million ) Quarter ended Year ended 31.03.2021 Audited 31.12.2020 Unaudited 31.03.2020 Audited 31.03.2021 Audited 31.03.2020 Audited I Revenue from operations a . Revenue from contracts with customers b . Other operating revenues Total revenue from operations ( I ) II Other income III Total income ( I + II ) IV Expenses Cost of materials consumed Purchases of stock - in - trade 84,313.8 916.0 87,818.4 85,229.8 549.4 88,367.8 1,110.0 3,149.5 86,339.8 91,517.3 80,780.3 1,069.1 81,849.4 1,022.3 82,871.7 331,391.8 3,589.6 334,981.4 8,355.2 343,336.6 323,251.7 5,123.3 328,375.0 6,359.8 334,734.8 17,468.1 14,276.0 12,095.8 61,531.3 55,152.3 7,418.2 8,683.4 9,106.4 31,751.7 34,143.7 Changes in inventories of finished goods , stock - in - trade and work - in - progress ( 2,478.7 ) Employee benefits expense 16,774.5 Finance costs Depreciation and amortisation expense Other expenses Net ( gain ) loss on foreign currency transactions 301.0 5,534.9 25,455.5 107.8 374.5 17,204.5 261.0 5,319.4 24,484.3 1,845.9 ( 6,382.2 ) 3,008.5 ( 716.3 ) Total expenses ( IV ) 70,581.3 69,886.8 16,518.9 517.8 5,753.8 27,231.6 1,420.7 74,490.9 68,622.3 63,623.5 1,414.3 3,027.3 20,799.5 94,781.1 ( 236.5 ) 272,281.5 20,527.8 102,705.5 ( 156.1 ) 282,032.5 V Profit / ( loss ) before exceptional items and tax ( III - IV ) 15,758.5 21,630.5 8,380.8 71,055.1 52,702.3 VI Exceptional items ( Refer Note 4 ) 6,728.1 2,606.4 43,061.4 2,606.4 VII Profit / ( loss ) before tax ( V - VI ) 9,030.4 21,630.5 5,774.4 27,993.7 50,095.9 VIII ( i ) Tax expense / ( credit ) for period / year 1,762.7 2,449.4 830.9 9,242.0 8,228.0 IX ( ii ) Tax expense / ( credit ) - Exceptional ( Refer Note 4 and 8 ) Profit / ( loss ) for the period before share of profit / ( loss ) of associates and joint venture ( VII - VIII ) ( 1,212.3 ) ( 4,095.1 ) 8,480.0 19,181.1 4,943.5 22,846.8 41,867.9 X Share of profit / ( loss ) of associates and joint venture ( net ) ( 55.9 ) XI Net Profit / ( loss ) after taxes and share of profit / ( loss ) of associates and joint venture but before non - controlling interests ( IX + X ) Non - controlling interests 8,424.1 ( 47.0 ) 19,134.1 ( 15.9 ) 4,927.6 ( 123.3 ) 22,723.5 ( 148.3 ) 41,719.6 ( 517.4 ) XII Net Profit / ( loss ) after taxes , share of profit / ( loss ) of associates and joint venture and non - controlling interests 8,941.5 609.3 18,524.8 929.2 3,998.4 ( 6,314.7 ) 29,038.2 4,070.3 37,649.3 XIII Other comprehensive income ( OCI ) A. ( i ) Items that will not be reclassified to profit or loss 2,158.4 ( ii ) Income tax relating to items that will not be reclassified to profit or loss ( 156.7 ) 1,078.0 42.7 B. ( i ) Items that may be reclassified to profit or loss ( 1,160.1 ) ( ii ) Income tax relating to items that may be reclassified to profit or loss Total other comprehensive income ( A + B ) ( XIII ) 45.3 886.9 XIV Total comprehensive income for the period ( XI + XIII ) Attributable to : - Owners of the Company - Non - controlling interests 9,311.0 ( 1,956.5 ) ( 161.1 ) ( 996.9 ) 18,137.2 ( 939.1 ) 29.80 13,174.6 221.5 12,486.8 17,414.4 3,233.9 ( 145.4 ) ( 4,031.6 ) ( 517.2 ) ( 1,460.3 ) 21,263.2 ( 1,314.1 ) 159.4 21,941.9 421.1 21,208.3 62,927.9 9,925.5 ( 614.5 ) 17,729.2 14,696.2 28,133.4 56,068.4 408.0 2,718.2 ( 6,870.2 ) 6,859.5 XV XVI Paid - up equity share capital - face value * 1 each Other equity 2,399.3 2,399.3 2,399.3 2,399.3 2,399.3 462,228.5 450,245.2 XVII Earnings per equity share of ₹ 1 each ( not annualised for quarters ) ( Basic ) ( Diluted ) 3.7 7.7 1.7 3.7 7.7 1.7 12.1 12.1 15.7 15.7 See accompanying notes to the audited consolidated financial results Research and development expenses incurred ( included above ) 5,386.5 5,515.2 5.205.1 21,028.2 19,251.7